logo-loader

Full interview: FSD Pharma 'thrilled' to begin Phase 1 studies of its micro-PEA drug in Australia

Published: 08:43 11 Mar 2020 EDT

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) BioSciences Division President Dr Ed Brennan tells Proactive the company has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in Victoria, Australia.

Dr Brennan says the drug has a broad application as an anti-inflammatory, where FSD where initially will be looking at pain and chronic pain indications.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

9 hours, 32 minutes ago